Follicular Lymphoma Treatment Market Research Report forecast 2017-2023
Summary - A new
market study, titled “Follicular Lymphoma Treatment Market: Global Market
Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016
and Forecast 2017 to 2023” has been featured on Wise Guy Reports.
Global Follicular Lymphoma
Treatment Market: By Treatment Type (Chemotherapy, Targeted Therapy,
Radiotherapy, Monoclonal Antibodies, Stem Cell Transplantation), By Route of
Administration (Oral, Parenteral), By End-User (Hospitals, Oncology Centers,
Academic Research Institutes) and Geography – Market Estimation, Dynamics,
Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Market Outline: Follicular Lymphoma Treatment Market
Follicular lymphoma is the second most common indolent
non-Hodgkin’s lymphoma and it develops when the body makes abnormal
B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma
include enlargement of lymph nodes in neck, abdomen, and groin, weight loss,
difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is
diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma
can be treated with chemotherapy, radiation therapy, targeted therapy, and stem
cell transplant.
Market Dynamics: Follicular Lymphoma Treatment Market
Rise in prevalence of follicular lymphoma, family history of
blood disorders, increase in R&D activities for the innovation of newer
drugs, and technological advancements in disease diagnosis are anticipated to
fuel the follicular lymphoma treatment market. Moreover, promising pipeline
products, innovation of newer therapies such as monoclonal antibodies, and
government initiations for the cancer management are expected to boost the
market over the forecast period. However, stringent regulatory policies for
drug approval, the high cost of treatment, and adverse effects associated with
the treatment are expected to hamper the growth of follicular lymphoma
treatment market over the forecast years.
Market Scope: Follicular Lymphoma Treatment Market
Follicular lymphoma treatment market is segmented on the
basis of treatment type, route of administration, end user, and region
Based on the treatment type, the market is segmented into
the following:
Chemotherapy
Alkylating Agents
Nucleoside Analogues
Anthracycline Derivatives
Others
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
Based on the route of administration, the market is
segmented into the following:
Oral
Parenteral
Others
Based on the end user, the market is segmented into the
following:
Hospitals
Retail Pharmacies
Oncology Centers
Academic Research Institutes
Based on region, the market is segmented into the following:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Market Summary: Follicular Lymphoma Treatment Market
Follicular lymphoma treatment market is poised to grow at
significant rate owing to increase in the R&D activities for the innovation
newer therapies and drugs. Most of the international players are actively
involved in the development of newer products. For instance, in December 2015,
Novartis announced phase IIa study results of CTL019 used in the treatment of
certain types of lymphoma including follicular lymphoma. Moreover, rising
adoption of monoclonal antibodies for targeted therapies propels the follicular
lymphoma treatment market. Furthermore, acquisitions and mergers,
collaborations, product approvals, and product launchings are the strategies
followed by the market players for gaining larger revenue share in follicular
lymphoma treatment market. For instance, in February 2017, Health Canada
approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated
follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology
Research are collaborated to identify the non-Hodgkin lymphoma patients with
EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical
trial of Tazemetostast in diffuse large B-cell lymphoma and follicular
lymphoma.
Regional Analysis: Follicular Lymphoma Treatment Market
Geographically, global follicular lymphoma treatment market
is segmented into North America, Europe, Asia Pacific, Latin America, and
Middle East and Africa. North America follicular lymphoma treatment market is
poised to grow at notable rate due to increase in the prevalence of follicular
lymphoma (according to American Cancer Society, approximately 20% of follicular
lymphoma cases observed among all types lymphoma patients), increase in R&D
activities for the innovation of newer drugs, an increase in healthcare
expenditure in the region. Europe follicular lymphoma treatment market is
expected to grow significantly due to the adoption of newer therapies,
sophisticated healthcare infrastructure, an increase in the prevalence of
follicular lymphoma due to change in lifestyle in the region. Asia Pacific
follicular lymphoma treatment market has a lucrative growth owing to the large
patient pool, increase in awareness about lymphoma treatment, and government
initiations for the prevention of cancer are expected to fuel the market in the
region. Latin America follicular lymphoma treatment market expected to grow at
moderate rate due to the expansion of business into the region by market
players, adoption of newer drugs, and economic growth are bolster the market. Middle
East and Africa follicular lymphoma treatment market have a growth attributed
to rising in awareness about lymphoma treatment, increase in the prevalence of
follicular lymphoma, and growing per capita income.
Competition Assessment: Follicular Lymphoma Treatment Market
Some of the players in the global follicular lymphoma
treatment market include:
Hoffmann La Roche Ltd. (Switzerland)
Novartis AG (Switzerland)
GlaxoSmithKline plc (U.K.)
Merck & Co. Inc. (U.S.)
AbbVie, Inc. (U.S.)
Bayer AG (Germany)
Epizyme Inc. (U.S.)
Bristol Myers Squibb (U.S.)
Johnson and Johnson Services Inc. (U.S.)
Notable Market Developments: Follicular Lymphoma Treatment
Market
In October 2017, U.S. Food and Drug Administration approved
Bayer AG’s Aliqopa (Copanlisib) for the treatment of follicular lymphoma
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/2868249-follicular-lymphoma-treatment-market-global-market-estimation-dynamics-regional-share
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and
governments around the globe.
Contact
Us:
NORAH
TRENT
Ph:
+162-825-80070
(US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment